keyword
MENU ▼
Read by QxMD icon Read
search

PSMA Gallium

keyword
https://www.readbyqxmd.com/read/29123013/-68-ga-psma-pet-ct-mapping-of-prostate-cancer-biochemical-recurrence-following-radical-prostatectomy-in-270-patients-with-psa-1-0ng-ml-impact-on-salvage-radiotherapy-planning
#1
Jérémie Calais, Johannes Czernin, Minsong Cao, Amar U Kishan, John V Hegde, Narek Shaverdian, Kiri A Sandler, Fang-I Chu, Chris R King, Michael L Steinberg, Isabel Rausher, Nina-Sophie Schmidt-Hegemann, Thorsten Poeppel, Philipp Hetkamp, Francesco Ceci, Ken Herrmann, Wolfgang P Fendler, Matthias Eiber, Nicholas G Nickols
Background: Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography ((68)Ga-PSMA-11 PET/CT) detects recurrent PCa with sensitivity superior to standard of care imaging at serum prostate specific antigen (PSA) values low enough to impact target volume delineations for routine SRT. OBJECTIVE: To i) map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients with serum PSA levels <1 ng/ml, ii) determine how often consensus clinical target volumes (CTV) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover (68)Ga-PSMA-11 PET/CT-defined disease, and iii) assess the potential impact of (68)Ga-PSMA-11 PET/CT on SRT...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29107272/-68-gallium-prostate-specific-membrane-antigen-pet-computed-tomography-for-primary-and%C3%A2-secondary-staging-in-prostate-cancer
#2
REVIEW
Michael Chaloupka, Annika Herlemann, Melvin D'Anastasi, Clemens C Cyran, Harun Ilhan, Christian Gratzke, Christian G Stief
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa). Until today, staging of patients with PCa relied mostly on morphologic features, such as size or shape, resulting in low detection rates in disease recurrence. PSMA PET imaging provides molecular information and, in combination with conventional imaging, offers improved sensitivity and specificity. This review discusses the benefits and limitations of PSMA imaging in the setting of primary staging and detection of recurrent disease in comparison with standard-of-care imaging techniques...
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29072055/diagnostic-challenges-in-prostate-cancer-and-68ga-psma-pet-imaging-a-game-changer
#3
Maseeh uz Zaman, Nosheen Fatima, Areeba Zaman, Mahwsih Sajid, Unaiza Zaman, Sidra Zaman
Prostate cancer (PC) is the most frequent solid tumor in men and the third most common cause of cancer mortality among men in developed countries. Current imaging modalities like ultrasound (US), computerized tomography (CT), magnetic resonance imaging (MRI) and choline based positron emission (PET) tracing have disappointing sensitivity for detection of nodal metastasis and small tumor recurrence. This poses a diagnostic challenge in staging of intermediate to high risk PC and restaging of patients with biochemical recurrence (PSA >0...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29067565/simple-mild-one-step-labelling-of-proteins-with-gallium-68-using-a-tris-hydroxypyridinone-bifunctional-chelator-a-68-ga-thp-scfv-targeting-the-prostate-specific-membrane-antigen
#4
Saima Nawaz, Gregory E D Mullen, Kavitha Sunassee, Jayanta Bordoloi, Philip J Blower, James R Ballinger
BACKGROUND: Labelling proteins with gallium-68 using bifunctional chelators is often problematic because of unsuitably harsh labelling conditions such as low pH or high temperature and may entail post-labelling purification. To determine whether tris(hydroxypyridinone) (THP) bifunctional chelators offer a potential solution to this problem, we have evaluated the labelling and biodistribution of a THP conjugate with a new single-chain antibody against the prostate-specific membrane antigen (PSMA), an attractive target for staging prostate cancer (PCa)...
October 25, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/29037965/prostate-cancer-specific-pet-radiotracers-a-review-on-the-clinical-utility-in-recurrent-disease
#5
Jaden D Evans, Krishan R Jethwa, Piet Ost, Scott Williams, Eugene D Kwon, Val J Lowe, Brian J Davis
Prostate cancer-specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine. Review of the literature generally favors PSMA-based agents for the detection of recurrence as a function of low PSA levels...
July 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29028767/prostate-specific-membrane-antigen-guided-salvage-lymph-node-dissection-in-recurrent-prostate-cancer-a-novel-technology-to-detect-lymph-node-metastases
#6
Tobias Maurer, Jürgen E Gschwend, Matthias Eiber
PURPOSE OF REVIEW: With Gallium (Ga)-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) as emerging imaging technique offering superior detection rates in biochemical recurrent prostate cancer, salvage lymph node dissection has gained increasing interest in localized oligometastatic prostate cancer. Currently, PSMA-targeting small molecules cannot only be linked to positron-emitting isotopes for imaging but also be labelled with γ-radiation emitting isotopes. These modified PSMA agents are evaluated for intraoperative guidance for resection of metastatic lymph nodes...
October 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28957842/comparison-of-68ga-psma-pet-ct-and-multiparametric-mri-for-staging-of-high-risk-prostate-cancer68ga-psma-pet-and-mri-in-prostate-cancer
#7
Shruti Tulsyan, Chandan J Das, Madhavi Tripathi, Amlesh Seth, Rajeev Kumar, Chandrasekhar Bal
INTRODUCTION: We carried out this study to compare Glu-NH-CO-NH-Lys-(Ahx) [Ga(HBED-CC)] [Ga prostate-specific membrane antigen-11 (PSMA-11)] PET with multiparametric MRI (mpMRI) for the staging of high-risk prostate cancer. PATIENTS AND METHODS: This was a prospective study in which 36 patients with high-risk prostate cancer were included. The criteria for inclusion were biopsy-proven prostate cancer with a serum prostate specific antigen of at least 20 and/or Gleason's score of at least 8...
December 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28950199/validation-of-a-al-18-f-psma-11-preparation-for-clinical-applications
#8
Ehab Al-Momani, Ina Israel, Samuel Samnick
Imaging prostate-specific membrane antigen (PSMA) using positron emission tomography (PET) has been presented so far as the most sensitive and specific with regard to prostate cancer detection, in particular in high-risk prostate cancer patients. Currently, it mainly features Gallium-68 ((68)Ga) labeled PSMA ligands, notably [(68)Ga]Glu-urea-Lys(Ahx)-HBED-CC ([(68)Ga]-PSMA-11) and [(68)Ga]DOTAGA-FFK (Sub-KuE termed ([(68)Ga]PSMA-I&T). However, (68)Ga has several shortcomings as radionuclide including a short half-life and non-ideal energies...
September 6, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28889366/performance-of-68-ga-psma-pet-ct-for-prostate-cancer-management-at-initial-staging-and-time-of-biochemical-recurrence
#9
REVIEW
Jason Bailey, Morand Piert
PURPOSE OF THE REVIEW: Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ((68)Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. RECENT FINDINGS: (68)Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, (68)Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that (68)Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL)...
September 9, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28775203/immunohistochemical-validation-of-psma-expression-measured-by-68-ga-psma-pet-ct-in-primary-prostate-cancer
#10
Nadine Woythal, Ruza Arsenic, Carsten Kempkensteffen, Kurt Miller, Jan-Carlo Janssen, Kai Huang, Marcus R Makowski, Winfried Brenner, Vikas Prasad
Aim: Gallium 68 ((68)Ga) prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) has a proven role in staging and restaging of prostate cancer (PCA) patients. The aims of this study were to evaluate the association of intraprostatic (68)Ga-PSMA PET/CT (PET) findings and prostate specific membrane antigen (PSMA) expression in immunohistochemical staining (IHC) and generate a cut-off value for the differentiation between benign prostate tissue from PCA. Methods: Data of 31 patients (mean 67...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28765999/a-rare-case-of-thymoma-first-detected-on-gallium-68-psma-pet-ct
#11
Hian Liang Huang, Angela Renayanti Dharmawan, Colin Jingxian Tan, Sue Ping Thang
No abstract text is available yet for this article.
November 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28753806/-68-ga-labeled-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-computed-tomography-for-prostate-cancer-a-systematic-review-and-meta-analysis
#12
REVIEW
Finn E von Eyben, Maria Picchio, Rie von Eyben, Handoo Rhee, Glenn Bauman
CONTEXT: (68)Gallium prostate-specific membrane antigen (PSMA) ligand (68)Ga-HBED-CC-PSMA ((68)Ga-PSMA) is a promising radiotracer for positron emission tomography (PET)/computed tomography (CT) of prostate cancer. OBJECTIVE: To conduct a meta-analysis to evaluate detection rate, diagnostic test accuracy, and adverse effects of (68)Ga-PSMA PET/CT or PET/magnetic resonance imaging (MRI) for staging of prostate cancer and for restaging of rising prostate-specific antigen (PSA) after initial treatment...
November 15, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28742337/gallium-complexation-stability-and-bioconjugation-of-1-4-7-triazacyclononane-derived-chelators-with-azaheterocyclic-arms
#13
Alexander Schmidtke, Tilman Läppchen, Christian Weinmann, Lorenz Bier-Schorr, Manfred Keller, Yvonne Kiefer, Jason P Holland, Mark D Bartholomä
We have recently introduced a 1,4,7-triazacyclononane (TACN) based chelating system with additional five-membered azaheterocyclic substituents for complexation of radioactive Cu(2+) ions. In this work, we investigated the complexation properties of these novel chelators with Ga(3+). In labeling experiments, we could show that the penta- and hexadentate imidazole derivatives NODIA-Me 4 and NOTI-Me 1 can be labeled with (68)Ga in specific activities up to ∼30 MBq nmol(-1), while the corresponding thiazole derivative NOTThia 2 did not label satisfactorily under identical conditions...
August 7, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28707038/-68-ga-psma-hbed-cc-uptake-in-osteolytic-osteoblastic-and-bone-marrow-metastases-of-prostate-cancer-patients
#14
Jan-Carlo Janssen, Nadine Woythal, Sebastian Meißner, Vikas Prasad, Winfried Brenner, Gerd Diederichs, Bernd Hamm, Marcus R Makowski
PURPOSE: The aim of this study was to evaluate potential differences in "Glu-NH-CO-NH-Lys" radio-labeled with [(68)Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([(68)Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients. PROCEDURES: This retrospective study was approved by the local ethics committee. Patients who received [(68)Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([(68)Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study...
December 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28685078/-68-ga-psma-pet-ct-for-the-detection-of-bone-metastasis-in-recurrent-prostate-cancer-and-a-psa-level-2-ng-ml-two-case-reports-and-a-literature-review
#15
Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho
Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28670175/a-comparative-study-of-68-gallium-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-and-magnetic-resonance-imaging-for-lymph-node-staging-in-high-risk-prostate-cancer-patients-an-initial-experience
#16
Manoj Gupta, Partha S Choudhury, Dibyamohan Hazarika, Sudhir Rawal
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of (68)Gallium ((68)Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent (68)Ga-PSMA PET-CT for staging (December 2014-December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28649735/diagnostic-sensitivity-of-tc-99m-hynic-psma-spect-ct-in-prostate-carcinoma-a-comparative-analysis-with-ga-68-psma-pet-ct
#17
Ismaheel O Lawal, Alfred O Ankrah, Neo P Mokgoro, Mariza Vorster, Alex Maes, Mike M Sathekge
BACKGROUND: Emerging data from published studies are demonstrating the superiority of Ga-68 PSMA PET/CT imaging in prostate cancer. However, the low yield of the Ge-68/Ga-68 from which Gallium-68 is obtained and fewer installed PET/CT systems compared to the SPECT imaging systems may limit its availability. We, therefore, evaluated in a head-to-head comparison, the diagnostic sensitivity of Ga-68 PSMA PET/CT and Tc-99m PSMA SPECT/CT in patients with prostate cancer. METHODS: A total of 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo Ga-68 PSMA PET/CT and Tc-99m HYNIC PSMA SPECT/CT...
August 2017: Prostate
https://www.readbyqxmd.com/read/28607878/targeted-prostate-biopsy-using-68-gallium-psma-pet-ct-for-image-guidance
#18
Demetrios N Simopoulos, Shyam Natarajan, Tonye A Jones, Wolfgang P Fendler, Anthony E Sisk, Leonard S Marks
Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a (68)Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusion technology, the lesion was target-biopsied and Gleason 3 + 4 = 7 (cancer core length of 12 mm) was identified. This case may herald a new application for PSMA scanning and prostate cancer imaging.
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28576423/-pet-ct-and-biochemical-recurrence-of-prostate-adenocarcinoma-added-value-of-68-ga-psma-11-when-18-f-fluorocholine-is-non-contributive
#19
M Gauthé, O Belissant, A Girard, J Zhang Yin, J Ohnona, A-S Cottereau, V Nataf, S Balogova, D Pontvert, T Lebret, B Guillonneau, O Cussenot, J-N Talbot
INTRODUCTION: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose (18)F-fluorocholine (FCH) PET/CT was non-contributive. PATIENTS AND METHOD: Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of (68)Ga-PSMA-11...
June 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28551611/-68-ga-psma-pet-ct-has-a-role-in-detecting-prostate-cancer-lesions-in-patients-with-recurrent-disease
#20
REVIEW
Claire Fitzpatrick, Olwyn Lynch, Laure Marignol
BACKGROUND/AIM: Early detection of recurrent πrostate cancer (PCa) lesions is paramount to allow patients to avail of localised salvage therapy options. The most significant reason for failure of salvage therapy is undetected metastatic disease. This demonstrates the need for a more accurate monitoring tool. The prostate-specific membrane antigen (PSMA) is increasingly investigated as a novel tracer for gallium 68 PET/CT to detect PCa lesions in patients with recurrent disease. MATERIALS AND METHODS: The Embase, Pubmed and the Cochrane databases were searched to identify studies investigating the accuracy of (68)Ga-PSMA-PET/CT in detecting PCa lesions...
June 2017: Anticancer Research
keyword
keyword
97903
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"